ENSC - CIK 0001716947
The table below shows Ensysce Biosciences, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $4.31M | $3.50M | $1.12M | $3.15M | $12.26M | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.24M |
| $5.34M |
| $2.29M |
| $5.30M |
| $15.66M |
| $226.46K |
| Property, plant & equipment | $124.13K | - | - | - | $151.00 | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $7.45M | $5.60M | $2.71M | $5.89M | $16.42M | $12.85M |
| Accounts payable | $3.27M | $1.36M | $1.94M | $2.94M | $301.10K | - |
| Total current liabilities | $4.57M | $2.21M | $3.33M | $9.46M | $16.48M | $260.40K |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $4.57M | $2.22M | $3.36M | $9.91M | $24.58M | $7.80M |
| Retained earnings | -$139.72M | -$129.54M | -$121.56M | -$110.93M | -$85.85M | -$1.21M |
| Total equity | $3.21M | $3.71M | -$322.86K | -$3.71M | -$7.88M | $5.00M |